Yoichiro Ogama

794 total citations
16 papers, 609 citations indexed

About

Yoichiro Ogama is a scholar working on Immunology, Molecular Biology and Genetics. According to data from OpenAlex, Yoichiro Ogama has authored 16 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Yoichiro Ogama's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers), Potassium and Related Disorders (2 papers) and Bioactive Compounds and Antitumor Agents (1 paper). Yoichiro Ogama is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers), Potassium and Related Disorders (2 papers) and Bioactive Compounds and Antitumor Agents (1 paper). Yoichiro Ogama collaborates with scholars based in Japan, United States and United Kingdom. Yoichiro Ogama's co-authors include Hiroyuki Okamoto, Mark G. Hibberd, Tomoki Yoneyama, Steve Warrington, Yuichi Sakurai, Richard O. Jenkins, Helen Jenkins, Kiyoshi Ashida, Akira Nishimura and Mitsune Tanimoto and has published in prestigious journals such as Nature Communications, Blood and Journal of Pharmaceutical Sciences.

In The Last Decade

Yoichiro Ogama

15 papers receiving 602 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoichiro Ogama Japan 10 237 202 190 116 110 16 609
Masafumi Nishino Japan 18 670 2.8× 432 2.1× 64 0.3× 46 0.4× 97 0.9× 59 862
Masao Hada Japan 11 111 0.5× 42 0.2× 60 0.3× 30 0.3× 54 0.5× 43 394
Kathleen Sanders United States 9 93 0.4× 45 0.2× 148 0.8× 58 0.5× 156 1.4× 14 409
A Hartmann Brazil 12 145 0.6× 27 0.1× 118 0.6× 34 0.3× 70 0.6× 42 374
Chi-Hung Cheng Taiwan 13 134 0.6× 78 0.4× 269 1.4× 43 0.4× 99 0.9× 15 758
Motoki Ninomiya Japan 14 336 1.4× 310 1.5× 91 0.5× 26 0.2× 299 2.7× 75 1.0k
Kisha A. Mitchell United States 14 265 1.1× 50 0.2× 85 0.4× 32 0.3× 173 1.6× 28 719
T Hisatsugu Japan 12 150 0.6× 39 0.2× 118 0.6× 46 0.4× 213 1.9× 48 485
Olivier Romano France 10 186 0.8× 44 0.2× 254 1.3× 82 0.7× 267 2.4× 14 827
G. Della Libera Italy 8 138 0.6× 46 0.2× 100 0.5× 34 0.3× 21 0.2× 10 527

Countries citing papers authored by Yoichiro Ogama

Since Specialization
Citations

This map shows the geographic impact of Yoichiro Ogama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoichiro Ogama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoichiro Ogama more than expected).

Fields of papers citing papers by Yoichiro Ogama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoichiro Ogama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoichiro Ogama. The network helps show where Yoichiro Ogama may publish in the future.

Co-authorship network of co-authors of Yoichiro Ogama

This figure shows the co-authorship network connecting the top 25 collaborators of Yoichiro Ogama. A scholar is included among the top collaborators of Yoichiro Ogama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoichiro Ogama. Yoichiro Ogama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ogama, Yoichiro, et al.. (2023). Safety, Tolerability, and Pharmacokinetics of Belumosudil, a Selective Rho-associated Coiled-coil-containing Protein Kinase 2 Inhibitor, in Healthy Japanese Volunteers: A PhaseⅠ, Randomized, Controlled Trial. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 54(5). 197–203. 2 indexed citations
2.
Haranaka, Miwa, et al.. (2023). Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults. Immunotherapy. 15(3). 149–161. 5 indexed citations
3.
Ogama, Yoichiro, Yuji Kumagai, Norio Komatsu, et al.. (2022). Phase 1 Clinical Trial of PPMX‐T003, a Novel Human Monoclonal Antibody Specific for Transferrin Receptor 1, to Evaluate Its Safety, Pharmacokinetics, and Pharmacodynamics. Clinical Pharmacology in Drug Development. 12(6). 579–587. 8 indexed citations
4.
Kitamura, Atsushi, et al.. (2022). Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI‐589 in Healthy Participants. Clinical Pharmacology in Drug Development. 11(10). 1136–1146. 4 indexed citations
5.
Haranaka, Miwa, James Baber, Yoichiro Ogama, et al.. (2021). A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nature Communications. 12(1). 7105–7105. 23 indexed citations
6.
Matsuki, Shunji, et al.. (2021). Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers. Pharmacology Research & Perspectives. 9(5). e00874–e00874. 5 indexed citations
7.
Fukase, Hiroyuki, Yoichiro Ogama, Tomohisa Saito, et al.. (2017). Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects. Drug Research. 67(6). 349–357. 18 indexed citations
8.
Jenkins, Helen, Yuichi Sakurai, Akira Nishimura, et al.. (2015). Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects. Alimentary Pharmacology & Therapeutics. 41(7). 636–648. 236 indexed citations
9.
Ogama, Yoichiro, et al.. (2013). A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. International Journal of Hematology. 97(3). 351–359. 20 indexed citations
10.
Morimoto, Kaori, Yoichiro Ogama, Akihiro Inano, et al.. (2011). Effect of Milk on the Pharmacokinetics of Oseltamivir in Healthy Volunteers. Journal of Pharmaceutical Sciences. 100(9). 3854–3861. 27 indexed citations
11.
12.
Masuda, Kozo, Akio Hiraki, Nobuharu Fujii, et al.. (2006). Loss or down‐regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Science. 98(1). 102–108. 47 indexed citations
13.
Ouchida, Mamoru, Yoshimi Jitsumori, Yoichiro Ogama, et al.. (2006). Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors. International Journal of Molecular Medicine. 18(5). 917–23. 13 indexed citations
14.
Ogama, Yoichiro, Mamoru Ouchida, Tadashi Yoshino, et al.. (2004). Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas. International Journal of Oncology. 25(3). 685–91. 21 indexed citations
15.
Oka, Takashi, Mamoru Ouchida, Yoichiro Ogama, et al.. (2002). Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas.. PubMed. 62(22). 6390–4. 166 indexed citations
16.
Dansako, Hiromichi, Fumihiko Ishimaru, Y. Takai, et al.. (2001). Molecular characterization of the ERGIC-53 gene in two Japanese patients with combined factor V-factor VIII deficiency. Annals of Hematology. 80(5). 292–294. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masafumi Nishino Breakdown of academic impact, for papers by Masao Hada Breakdown of academic impact, for papers by Kathleen Sanders Breakdown of academic impact, for papers by A Hartmann Breakdown of academic impact, for papers by Chi-Hung Cheng Breakdown of academic impact, for papers by Motoki Ninomiya Breakdown of academic impact, for papers by Kisha A. Mitchell Breakdown of academic impact, for papers by T Hisatsugu Breakdown of academic impact, for papers by Olivier Romano Breakdown of academic impact, for papers by G. Della Libera
Rankless by CCL
2026